Arthritis sufferers who undergo psychological counseling and learn skills for coping with pain have less disability and better quality of life, according to a new systematic review.
Efforts to create a safe haven from allergens, for example, actually have contributed to the alarming rise of this irritating and even deadly malady, according to Gregg Mitman, William Coleman Professor of the History of Science at the University of Wisconsin-Madison.
Physicians and staff at UCSD Medical Center say this is the perfect time to remind San Diegans that they can take care of their skin and still have fun in the sun.
The U.S. Food and Drug Administration (FDA) announced the approval of Neupro (rotigotine transdermal system), a skin patch designed to treat symptoms of early Parkinson’s disease.
New scientific evidence is helping to build a compelling case for oncolytic viruses as a first-line and adjunctive treatment for many cancers. Reovirus, a non-pathogenic virus under development at Calgary, Alberta-based Oncolytics Biotech, has shown powerful anti-cancer activity against cultured tumor cells, in animal models, and in human clinical trials. Oncolytics’ proprietary reovirus formulation, Reolysin?, is active against numerous cancers, including intractable sarcomas and melanomas.
The Linda Lehrer Memorial Walk for Lung Cancer will be held at noon Saturday, May 19, at the Webster Thomas Field House. Webster Schroeder High School senior Allyssa Lehrer is organizing the event as a tribute to her aunt who died last fall and to fund lung cancer research at the James P. Wilmot Cancer Center.
Fabre-Kramer Pharmaceuticals Inc. and GlaxoSmithKline announced today the submission by Fabre-Kramer to the Food and Drug Administration of an amendment to the New Drug Application for gepirone extended release (ER).
While many migraine sufferers experience traditional symptoms such as nausea or sensitivity to light and sound, migraine attacks can also involve symptoms like neck pain or sinus pain that are not traditionally associated with migraine headaches.
Only 8 percent of people identified as drug abusers, and fewer than 40 percent of those diagnosed with drug dependence, have ever gotten any kind of intervention or treatment, according to the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC).
More than 500 scientists, clinicians and public health specialists met today at the National Institutes of Health (NIH) to discuss the latest research on drug abuse and the evolving epidemic of HIV/AIDS. This is the first-ever two-day public meeting at NIH to include a focus on non-injection drug use and HIV transmission.